Which has preferable valuation and earnings, TELA or PDEX?

Pro-Dex has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.64 -$38.83M -$0.77 N/A Pro-Dex $77.55M 2.70 $13.66M $4.13 15.84

Is TELA or PDEX more profitable?

Pro-Dex has a net margin of 17.62% compared to TELA Bio's net margin of -51.53%. Pro-Dex's return on equity of 25.13% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -51.53% -1,320.81% -59.39% Pro-Dex 17.62% 25.13% 16.02%

Which has stronger earnings & valuation, TELA or PROF?

TELA Bio has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.64 -$38.83M -$0.77 N/A Profound Medical $16.10M 13.69 -$42.57M -$0.98 N/A

Is TELA or PROF more profitable?

TELA Bio has a net margin of -51.53% compared to Profound Medical's net margin of -171.57%. Profound Medical's return on equity of -63.03% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -51.53% -1,320.81% -59.39% Profound Medical -171.57% -63.03% -51.24%

Does the media prefer TELA or PROF?

In the previous week, TELA Bio had 6 more articles in the media than Profound Medical. MarketBeat recorded 8 mentions for TELA Bio and 2 mentions for Profound Medical. TELA Bio's average media sentiment score of 0.54 beat Profound Medical's score of 0.00 indicating that TELA Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TELA Bio 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STIM or TELA more profitable?

Neuronetics has a net margin of -19.62% compared to TELA Bio's net margin of -51.53%. Neuronetics' return on equity of -125.11% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% TELA Bio -51.53% -1,320.81% -59.39%

Is FOCL or TELA more profitable?

TELA Bio has a net margin of -51.53% compared to FocalTherics' net margin of -56.26%. FocalTherics' return on equity of -248.00% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% TELA Bio -51.53% -1,320.81% -59.39%

Does the media refer more to FOCL or TELA?

In the previous week, TELA Bio had 7 more articles in the media than FocalTherics. MarketBeat recorded 8 mentions for TELA Bio and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.02 beat TELA Bio's score of 0.54 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TELA Bio 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, TELA or OWLT?

TELA Bio has higher earnings, but lower revenue than Owlet. Owlet is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.64 -$38.83M -$0.77 N/A Owlet $105.70M 1.40 -$39.68M -$0.75 N/A

Is TELA or OWLT more profitable?

Owlet has a net margin of -8.61% compared to TELA Bio's net margin of -51.53%. Owlet's return on equity of -601.24% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -51.53% -1,320.81% -59.39% Owlet -8.61% -601.24% -15.96%

Does the media prefer TELA or OWLT?

In the previous week, TELA Bio had 7 more articles in the media than Owlet. MarketBeat recorded 8 mentions for TELA Bio and 1 mentions for Owlet. Owlet's average media sentiment score of 1.97 beat TELA Bio's score of 0.54 indicating that Owlet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TELA Bio 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Owlet 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

TELA Bio (TELA) Competitors

$1.09 -0.05 (-4.39%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 -0.01 (-0.55%)

As of 07:30 PM Eastern

Compare

TELA vs. PDEX, PROF, STIM, FOCL, and OWLT

Should you buy TELA Bio stock or one of its competitors? TELA Bio's main competitors and comparable companies include Pro-Dex (PDEX), Profound Medical (PROF), Neuronetics (STIM), FocalTherics (FOCL), and Owlet (OWLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TELA Bio compare to Pro-Dex?

TELA Bio (NASDAQ:TELA) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Pro-Dex has a net margin of 17.62% compared to TELA Bio's net margin of -51.53%. Pro-Dex's return on equity of 25.13% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Pro-Dex	17.62%	25.13%	16.02%

TELA Bio has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

TELA Bio presently has a consensus target price of $2.14, indicating a potential upside of 87.97%. Pro-Dex has a consensus target price of $74.00, indicating a potential upside of 13.15%. Given TELA Bio's higher probable upside, research analysts clearly believe TELA Bio is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 1.1% of TELA Bio shares are held by insiders. Comparatively, 45.9% of Pro-Dex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pro-Dex has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.64	-$38.83M	-$0.77	N/A
Pro-Dex	$77.55M	2.70	$13.66M	$4.13	15.84

In the previous week, TELA Bio had 8 more articles in the media than Pro-Dex. MarketBeat recorded 8 mentions for TELA Bio and 0 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.00 beat TELA Bio's score of 0.54 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
TELA Bio	Positive
Pro-Dex	Positive

Summary

Pro-Dex beats TELA Bio on 11 of the 17 factors compared between the two stocks.

How does TELA Bio compare to Profound Medical?

TELA Bio (NASDAQ:TELA) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

TELA Bio currently has a consensus price target of $2.14, indicating a potential upside of 87.97%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 90.71%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

TELA Bio has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

In the previous week, TELA Bio had 6 more articles in the media than Profound Medical. MarketBeat recorded 8 mentions for TELA Bio and 2 mentions for Profound Medical. TELA Bio's average media sentiment score of 0.54 beat Profound Medical's score of 0.00 indicating that TELA Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TELA Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TELA Bio has a net margin of -51.53% compared to Profound Medical's net margin of -171.57%. Profound Medical's return on equity of -63.03% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Profound Medical	-171.57%	-63.03%	-51.24%

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 1.1% of TELA Bio shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TELA Bio has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.64	-$38.83M	-$0.77	N/A
Profound Medical	$16.10M	13.69	-$42.57M	-$0.98	N/A

Summary

TELA Bio beats Profound Medical on 10 of the 17 factors compared between the two stocks.

How does TELA Bio compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

TELA Bio has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$155.10M	1.08	-$39M	-$0.44	N/A
TELA Bio	$80.28M	0.64	-$38.83M	-$0.77	N/A

Neuronetics presently has a consensus price target of $4.67, suggesting a potential upside of 112.12%. TELA Bio has a consensus price target of $2.14, suggesting a potential upside of 87.97%. Given Neuronetics' stronger consensus rating and higher probable upside, research analysts clearly believe Neuronetics is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, TELA Bio had 8 more articles in the media than Neuronetics. MarketBeat recorded 8 mentions for TELA Bio and 0 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.76 beat TELA Bio's score of 0.54 indicating that Neuronetics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuronetics	Positive
TELA Bio	Positive

Neuronetics has a net margin of -19.62% compared to TELA Bio's net margin of -51.53%. Neuronetics' return on equity of -125.11% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
TELA Bio	-51.53%	-1,320.81%	-59.39%

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 1.1% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Neuronetics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Summary

Neuronetics beats TELA Bio on 10 of the 15 factors compared between the two stocks.

How does TELA Bio compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

TELA Bio has a net margin of -51.53% compared to FocalTherics' net margin of -56.26%. FocalTherics' return on equity of -248.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
TELA Bio	-51.53%	-1,320.81%	-59.39%

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 1.1% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

FocalTherics has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

FocalTherics currently has a consensus target price of $7.75, indicating a potential upside of 83.22%. TELA Bio has a consensus target price of $2.14, indicating a potential upside of 87.97%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

FocalTherics has higher earnings, but lower revenue than TELA Bio. FocalTherics is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.25	-$29.25M	-$1.03	N/A
TELA Bio	$80.28M	0.64	-$38.83M	-$0.77	N/A

In the previous week, TELA Bio had 7 more articles in the media than FocalTherics. MarketBeat recorded 8 mentions for TELA Bio and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.02 beat TELA Bio's score of 0.54 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TELA Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TELA Bio beats FocalTherics on 10 of the 17 factors compared between the two stocks.

How does TELA Bio compare to Owlet?

TELA Bio (NASDAQ:TELA) and Owlet (NYSE:OWLT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

TELA Bio has higher earnings, but lower revenue than Owlet. Owlet is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.64	-$38.83M	-$0.77	N/A
Owlet	$105.70M	1.40	-$39.68M	-$0.75	N/A

In the previous week, TELA Bio had 7 more articles in the media than Owlet. MarketBeat recorded 8 mentions for TELA Bio and 1 mentions for Owlet. Owlet's average media sentiment score of 1.97 beat TELA Bio's score of 0.54 indicating that Owlet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TELA Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Owlet	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

TELA Bio presently has a consensus price target of $2.14, suggesting a potential upside of 87.97%. Owlet has a consensus price target of $15.00, suggesting a potential upside of 195.86%. Given Owlet's higher possible upside, analysts plainly believe Owlet is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Owlet has a net margin of -8.61% compared to TELA Bio's net margin of -51.53%. Owlet's return on equity of -601.24% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Owlet	-8.61%	-601.24%	-15.96%

TELA Bio has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Owlet has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 72.6% of Owlet shares are owned by institutional investors. 1.1% of TELA Bio shares are owned by company insiders. Comparatively, 36.2% of Owlet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Owlet beats TELA Bio on 10 of the 16 factors compared between the two stocks.

Get TELA Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELA vs. The Competition

Export

Metric	TELA Bio	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.46M	$5.56B	$7.19B	$13.39B
Dividend Yield	N/A	1.78%	2.53%	18.16%
P/E Ratio	-1.42	25.18	273.36	26.35
Price / Sales	0.61	83.78	591.83	96.77
Price / Cash	N/A	32.45	79.41	53.24
Price / Book	6.81	5.97	11.04	6.33
Net Income	-$38.83M	$146.97M	$3.49B	$381.26M
7 Day Performance	-12.10%	-0.73%	-2.30%	-0.61%
1 Month Performance	32.68%	-4.79%	-7.05%	-4.84%
1 Year Performance	-28.05%	1.14%	5.64%	1.12%

TELA Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELA TELA Bio	4.1584 of 5 stars	$1.09 -4.4%	$2.14 +96.6%	-26.9%	$51.46M	$80.28M	N/A	218	News Coverage
PDEX Pro-Dex	3.5907 of 5 stars	$70.74 -1.2%	$74.00 +4.6%	+92.2%	$226.29M	$77.55M	17.12	206	Positive News
PROF Profound Medical	1.769 of 5 stars	$5.83 -1.5%	$11.50 +97.3%	+6.2%	$213.01M	$16.10M	N/A	162	Positive News
STIM Neuronetics	4.2782 of 5 stars	$2.40 -6.4%	$4.67 +94.9%	-22.8%	$182.50M	$149.16M	N/A	658	News Coverage Positive News
FOCL FocalTherics	4.5911 of 5 stars	$4.61 +1.8%	$7.75 +68.1%	N/A	$173.01M	$70.53M	N/A	230	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELA) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TELA Bio (TELA) Competitors

TELA vs. PDEX, PROF, STIM, FOCL, and OWLT

How does TELA Bio compare to Pro-Dex?

Summary

How does TELA Bio compare to Profound Medical?

Summary

How does TELA Bio compare to Neuronetics?

Summary

How does TELA Bio compare to FocalTherics?

Summary

How does TELA Bio compare to Owlet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA vs. The Competition

TELA Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TELA Bio (TELA) Competitors

TELA vs. PDEX, PROF, STIM, FOCL, and OWLT

How does TELA Bio compare to Pro-Dex?

Is TELA or PDEX more profitable?

Which has more risk & volatility, TELA or PDEX?

Do analysts prefer TELA or PDEX?

Do institutionals & insiders have more ownership in TELA or PDEX?

Which has preferable valuation and earnings, TELA or PDEX?

Does the media prefer TELA or PDEX?

Summary

How does TELA Bio compare to Profound Medical?

Do analysts prefer TELA or PROF?

Which has more risk and volatility, TELA or PROF?

Does the media prefer TELA or PROF?

Is TELA or PROF more profitable?

Do insiders & institutionals have more ownership in TELA or PROF?

Which has stronger earnings & valuation, TELA or PROF?

Summary

How does TELA Bio compare to Neuronetics?

Which has stronger valuation and earnings, STIM or TELA?

Do analysts rate STIM or TELA?

Does the media refer more to STIM or TELA?

Is STIM or TELA more profitable?

Do institutionals & insiders have more ownership in STIM or TELA?

Which has more risk & volatility, STIM or TELA?

Summary

How does TELA Bio compare to FocalTherics?

Is FOCL or TELA more profitable?

Do institutionals and insiders believe in FOCL or TELA?

Which has more risk and volatility, FOCL or TELA?

Do analysts rate FOCL or TELA?

Which has higher valuation and earnings, FOCL or TELA?

Does the media refer more to FOCL or TELA?

Summary

How does TELA Bio compare to Owlet?

Which has better earnings & valuation, TELA or OWLT?

Does the media prefer TELA or OWLT?

Do analysts rate TELA or OWLT?

Is TELA or OWLT more profitable?

Which has more risk and volatility, TELA or OWLT?

Do institutionals and insiders hold more shares of TELA or OWLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA vs. The Competition

TELA Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools